ZA200107718B - Process for the preparation of a bioavailable oral dosage form of cefuroxime axetil. - Google Patents
Process for the preparation of a bioavailable oral dosage form of cefuroxime axetil. Download PDFInfo
- Publication number
- ZA200107718B ZA200107718B ZA200107718A ZA200107718A ZA200107718B ZA 200107718 B ZA200107718 B ZA 200107718B ZA 200107718 A ZA200107718 A ZA 200107718A ZA 200107718 A ZA200107718 A ZA 200107718A ZA 200107718 B ZA200107718 B ZA 200107718B
- Authority
- ZA
- South Africa
- Prior art keywords
- cefuroxime axetil
- dosage form
- amorphous
- preparation
- oral dosage
- Prior art date
Links
- KEJCWVGMRLCZQQ-YJBYXUATSA-N Cefuroxime axetil Chemical compound N([C@@H]1C(N2C(=C(COC(N)=O)CS[C@@H]21)C(=O)OC(C)OC(C)=O)=O)C(=O)\C(=N/OC)C1=CC=CO1 KEJCWVGMRLCZQQ-YJBYXUATSA-N 0.000 title claims description 57
- 229960002620 cefuroxime axetil Drugs 0.000 title claims description 56
- 238000000034 method Methods 0.000 title claims description 20
- 238000002360 preparation method Methods 0.000 title claims description 9
- 239000006186 oral dosage form Substances 0.000 title claims description 7
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 12
- 239000000203 mixture Substances 0.000 claims description 12
- HWPKGOGLCKPRLZ-UHFFFAOYSA-M monosodium citrate Chemical compound [Na+].OC(=O)CC(O)(C([O-])=O)CC(O)=O HWPKGOGLCKPRLZ-UHFFFAOYSA-M 0.000 claims description 5
- 235000018342 monosodium citrate Nutrition 0.000 claims description 5
- 239000002524 monosodium citrate Substances 0.000 claims description 5
- 159000000000 sodium salts Chemical group 0.000 claims description 5
- 238000005550 wet granulation Methods 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 239000002253 acid Substances 0.000 claims 1
- 238000009472 formulation Methods 0.000 description 11
- 238000004090 dissolution Methods 0.000 description 7
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 6
- 239000008187 granular material Substances 0.000 description 6
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 4
- 239000011230 binding agent Substances 0.000 description 4
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 229940016286 microcrystalline cellulose Drugs 0.000 description 4
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 4
- 239000008108 microcrystalline cellulose Substances 0.000 description 4
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- -1 1-acetoxyethyl ester Chemical class 0.000 description 3
- 229920002785 Croscarmellose sodium Polymers 0.000 description 3
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 3
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 3
- 230000003115 biocidal effect Effects 0.000 description 3
- 229910000019 calcium carbonate Inorganic materials 0.000 description 3
- 229960001668 cefuroxime Drugs 0.000 description 3
- JFPVXVDWJQMJEE-IZRZKJBUSA-N cefuroxime Chemical compound N([C@@H]1C(N2C(=C(COC(N)=O)CS[C@@H]21)C(O)=O)=O)C(=O)\C(=N/OC)C1=CC=CO1 JFPVXVDWJQMJEE-IZRZKJBUSA-N 0.000 description 3
- 229960001681 croscarmellose sodium Drugs 0.000 description 3
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
- 229940069328 povidone Drugs 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- 229930186147 Cephalosporin Natural products 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229940124587 cephalosporin Drugs 0.000 description 2
- 230000001186 cumulative effect Effects 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 238000001694 spray drying Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- JFPVXVDWJQMJEE-QMTHXVAHSA-N Cefuroxime Chemical compound N([C@@H]1C(N2C(=C(COC(N)=O)CS[C@@H]21)C(O)=O)=O)C(=O)C(=NOC)C1=CC=CO1 JFPVXVDWJQMJEE-QMTHXVAHSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 229950003588 axetil Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 229960003563 calcium carbonate Drugs 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 229940047496 ceftin Drugs 0.000 description 1
- 150000001780 cephalosporins Chemical class 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 239000002178 crystalline material Substances 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 235000020937 fasting conditions Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229940083542 sodium Drugs 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
- A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cephalosporin Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN453DE1999 IN190831B (fr) | 1999-03-19 | 1999-03-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200107718B true ZA200107718B (en) | 2002-05-09 |
Family
ID=11089857
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200107718A ZA200107718B (en) | 1999-03-19 | 2001-09-18 | Process for the preparation of a bioavailable oral dosage form of cefuroxime axetil. |
Country Status (3)
| Country | Link |
|---|---|
| US (1) | US6346530B1 (fr) |
| IN (1) | IN190831B (fr) |
| ZA (1) | ZA200107718B (fr) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100448879C (zh) * | 2004-07-22 | 2009-01-07 | 北京化工大学 | 一种无定型头孢呋辛酯的制备方法 |
| DE102005019458A1 (de) * | 2005-04-25 | 2006-10-26 | Grünenthal GmbH | Darreichungsform mit verbesserter Freisetzung von Cefuroximaxetil |
| WO2007063552A1 (fr) | 2005-12-02 | 2007-06-07 | Lupin Limited | Formulations stables de céphalosporines au goût masqué |
| CN102697747A (zh) * | 2012-06-13 | 2012-10-03 | 广州南新制药有限公司 | 一种头孢呋辛酯的分散片 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1094545A (fr) | 1976-02-16 | 1981-01-27 | Michael Gregson | Traduction non-disponible |
| NL193682C (nl) * | 1987-05-14 | 2000-07-04 | Glaxo Group Ltd | Beklede cefuroximaxetilsamenstelling. |
| US5063224A (en) * | 1990-07-09 | 1991-11-05 | Eli Lilly And Company | R-cefuroxime axetil |
| NZ299077A (en) * | 1996-07-26 | 1998-06-26 | Apotex Inc | Preparation of amorphous cefuroxime axetil (a cephalosporin derivative) by dissolving crystalline cefuroxim axetil in a highly polar solvent, typically dmso and/or dmf |
| IN186539B (fr) * | 1997-09-29 | 2001-09-29 | Ranbaxy Lab Ltd |
-
1999
- 1999-03-19 IN IN453DE1999 patent/IN190831B/en unknown
- 1999-08-04 US US09/366,986 patent/US6346530B1/en not_active Expired - Fee Related
-
2001
- 2001-09-18 ZA ZA200107718A patent/ZA200107718B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IN190831B (fr) | 2003-08-23 |
| US6346530B1 (en) | 2002-02-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1165051B1 (fr) | Procede de preparation d'une forme posologique orale biodisponible de cefuroxime axetil | |
| US5837292A (en) | Granulate for the preparation of fast-disintegrating and fast-dissolving compositions containing a high amount of drug | |
| US6610326B2 (en) | Divalproex sodium tablets | |
| US6932981B2 (en) | Rapidly disintegrating sustained release cefuroxime axetil composition | |
| JP5671560B2 (ja) | 固体投与形中のテトラサイクリン金属錯体 | |
| EP0710653B1 (fr) | Sels de la néfazodone ayant une vitesse de dissolution améliorée | |
| WO1998022105A1 (fr) | Preparation en comprimes | |
| US20080118564A1 (en) | Pharmaceutical Composition Containing Candesartan Cilexetil as Lipophilic Crystalline Substance | |
| CA2662265A1 (fr) | Compositions d'imatinib | |
| AU759517B2 (en) | Compositions comprising cefuroxime axetil | |
| NZ516760A (en) | Non-crystalline cefuroxime axetil solid dispersant, process for preparing same and composition for oral administration thereof | |
| US6346530B1 (en) | Process for the preparation of a bioavailable oral dosage form of cefuroxime axetil | |
| CA2209868C (fr) | Compositions pharmaceutiques a base de cefuroxime axetil | |
| KR20220091767A (ko) | 사쿠비트릴 발사르탄 하이브리드 화합물 또는 그 약제학적으로 허용되는 염을 유효성분으로 포함하는 약제학적 조성물 | |
| WO1989006959A1 (fr) | Preparation pharmaceutique a liberation amelioree | |
| KR100475260B1 (ko) | 높은양의약을함유하는,신속-붕해되고신속-용해되는조성물제조용과립 | |
| KR101428149B1 (ko) | 이매티닙메실산염 함유 과립, 이를 포함하는 경구용 속방성 정제 조성물 및 그것의 제조방법 | |
| KR910004481B1 (ko) | 용출성이 개량된 제제 조성물 | |
| DE60003796T2 (de) | Verfahren zur herstellung einer bioverfügbaren oralen darreichungsform von cefuroxim-axetil | |
| JPS6156219B2 (fr) | ||
| US20040105886A1 (en) | Divalproex sodium tablets | |
| KR100307251B1 (ko) | 아시클로버 확산정의 조성물 및 그의 제조방법 | |
| JPS63126824A (ja) | 経口用セフアロスポリン組成物 | |
| JPS63183533A (ja) | 経口用セフアロスポリン組成物 | |
| MXPA06000699A (en) | A doxycycline metal complex in a solid dosage form |